Indication
Conditioning prior to allogeneic hematopoietic stem cell transplant
Conditioning prior to allogeneic hematopoietic stem cell transplant refers to a procedural preparatory state rather than an intrinsic disease entity. Read more about Conditioning prior to allogeneic hematopoietic stem cell transplant
32 drugs 29 manufacturers
Drugs that treat it
Common Conditioning prior to allogeneic hematopoietic stem cell transplant therapies.
MYLERAN (busulfan)
BUSULFEX (busulfan)
BUSULFEX (busulfan)
THIOTEPA
MYLERAN (busulfan)
BUSULFAN
TEPADINA (thiotepa)
BUSULFAN
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonConditioning prior to allogeneic hematopoietic stem cell transplant refers to a procedural preparatory state rather than an intrinsic disease entity.
Administered to pediatric or adult patients with hematologic malignancies, marrow failure syndromes, or congenital immunodeficiencies, this clinical state involves intensive pre-transplant cytoreduction and immunosuppression.
Pathophysiologically, the regimen—delivered via myeloablative, reduced-intensity, or non-myeloablative intensities—targets the host hematopoietic and immune systems through profound myelodepletion and lymphodepletion.
This eliminates residual diseased cells, empties marrow stem cell niches, and suppresses recipient immune responses to prevent graft rejection and permit successful donor cell engraftment.
- nih.gov
Conditioning prior to allogeneic hematopoietic stem cell transplant refers to a procedural preparatory state rather than an intrinsic disease entity Administered to pediatric or adult patients with hematologic malignancies, marrow failure syndromes, or congenital immunodeficiencies, this clinical state involves intensive pre-transplant cytoreduction and immunosuppression This eliminates residual diseased cells, empties marrow stem cell niches, and suppresses recipient immune responses to prevent...
- nih.gov
Conditioning prior to allogeneic hematopoietic stem cell transplant refers to a procedural preparatory state rather than an intrinsic disease entity Administered to pediatric or adult patients with hematologic malignancies, marrow failure syndromes, or congenital immunodeficiencies, this clinical state involves intensive pre-transplant cytoreduction and immunosuppression Pathophysiologically, the regimen—delivered via myeloablative, reduced-intensity, or non-myeloablative intensities—targets the...
- ashpublications.org
Administered to pediatric or adult patients with hematologic malignancies, marrow failure syndromes, or congenital immunodeficiencies, this clinical state involves intensive pre-transplant cytoreduction and immunosuppression
- bhs.be
Pathophysiologically, the regimen—delivered via myeloablative, reduced-intensity, or non-myeloablative intensities—targets the host hematopoietic and immune systems through profound myelodepletion and lymphodepletion This eliminates residual diseased cells, empties marrow stem cell niches, and suppresses recipient immune responses to prevent graft rejection and permit successful donor cell engraftment
Personalize your experience
Follow Conditioning prior to allogeneic hematopoietic stem cell transplant and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.